OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Chemistry and Laboratory Medicine is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis	1251
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection	834
Laboratory abnormalities in patients with COVID-2019 infection	604
Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)	430
The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks	241
Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics	227
Routine blood tests as a potential diagnostic tool for COVID-19	164
Laboratory abnormalities in children with novel coronavirus disease 2019	151
Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence	139
Development, evaluation, and validation of machine learning models for COVID-19 detection based on routine blood tests	99
Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays	94
Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation	91
COVID-19 infections are also affected by human ACE1 D/I polymorphism	87
Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)	85
Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy	81
The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study	73
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody	72
Low levels of total and ionized calcium in blood of COVID-19 patients	70
Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors	62
The utility of measurement uncertainty in medical laboratories	61
The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019	60
Evaluation of the automated LIAISON^® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies	59
SARS-CoV-2 serosurvey in health care workers of the Veneto Region	58
IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2	56
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers	56

Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019	52
COVID-19: progression of disease and intravascular coagulation – present status and future perspectives	51
Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?	50
Variability of cycle threshold values in an external quality assessment scheme for detection of the SARS-CoV-2 virus genome by RT-PCR	47
SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics	47
Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing	47
Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children	47
The internal quality control in the traceability era	45
IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection	44
Monocyte distribution width (MDW) as a screening tool for sepsis in the Emergency Department	43
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid	43
Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study	43
Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers	42
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series	42
The emerging role of cell senescence in atherosclerosis	41
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine	40